Systematic Evaluation and Meta-Analysis of the Efficacy and Safety of Shenfu Injection in the Treatment of Septic Cardiomyopathy

Objective: To evaluate the efficacy and safety of Shenfu injection in treatment septic cardiomyopathy. Methods: Literatures on for sepsis published from establishment each database to December 31, 2020, were searched by computer; Cochrane risk-of-bias tool was used evaluating quality literatures, Review Manager 5.4 software meta-analysis. Results: Twenty random controlled trials (RCTs) included, with a total 1,179 patients; meta-analysis showed that routine Western medicine combined can reduce 28-day mortality, length hospital stay, cardiac troponin I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP) as well improve left ventricular ejection fraction (LVEF) low incidence adverse reactions. Conclusion: further myocardial injury patients function prognosis